Cardiac hypertrophy diminished the effects of isoproterenol on delayed rectifier potassium current in rat heart

Tomohiko Sakatani1, Takeshi Shirayama, Taku Yamamoto

  • 1Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. sakatani@koto.kpu-m.ac.jp

Insights

In hypertrophic rat hearts, reduced potassium current (I(K)) prolongs action potential duration. Isoproterenol fails to stimulate I(K) due to increased phosphodiesterase activity, worsening heart dysfunction.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Molecular Cardiology

Background:

  • Left ventricular hypertrophy (LVH) alters cardiac electrophysiology.
  • Sympathetic nerve activity influences ion channel function in the heart.

Purpose of the Study:

  • To investigate the relationship between sympathetic stimulation and potassium current (I(K)) in a rat model of cardiac hypertrophy.
  • To elucidate the mechanisms behind altered action potential duration (APD) in hypertrophic hearts.

Main Methods:

  • Induction of LVH via suprarenal aortic constriction in rats.
  • Whole-cell patch clamp technique to measure ion currents (I(K), I(Ca)) and APD.
  • Pharmacological stimulation with isoproterenol, forskolin, and IBMX.

Main Results:

  • Hypertrophic hearts showed a 28.2% decrease in I(K), leading to prolonged APD(90).
  • Isoproterenol failed to stimulate I(K) in hypertrophic hearts, unlike in sham controls.
  • Isoproterenol increased L-type calcium current (I(Ca)) similarly in both groups, further prolonging APD in hypertrophic hearts.
  • Forskolin did not enhance I(K) in hypertrophy, but IBMX did, suggesting a role for phosphodiesterase.

Conclusions:

  • Enhanced phosphodiesterase activity in hypertrophic hearts impairs isoproterenol-mediated I(K) stimulation.
  • This impairment contributes to excessive action potential duration prolongation and cardiac dysfunction in hypertrophy.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...